Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (34)
  • Open Access

    ARTICLE

    Apatinib reduces liver cancer cell multidrug resistance by modulating NF-κB signaling pathway

    XIAOXIAO HE1, XUEQING ZHOU2, JINPENG ZHANG2, MINGFEI ZHANG2, DANHONG ZENG2, HENG ZHANG1, SHUCAI YANG2,*

    BIOCELL, Vol.48, No.9, pp. 1331-1341, 2024, DOI:10.32604/biocell.2024.052625 - 04 September 2024

    Abstract Objectives: This investigation aimed to elucidate the inhibitory impact of apatinib on the multidrug resistance of liver cancer both in vivo and in vitro. Methods: To establish a Hep3B/5-Fu resistant cell line, 5-Fu concentrations were gradually increased in the culture media. Hep3B/5-Fu cells drug resistance and its alleviation by apatinib were confirmed via flow cytometry and Cell Counting Kit 8 (CCK8) test. Further, Nuclear factor kappa B (NF-κB) siRNA was transfected into Hep3B/5-Fu cells to assess alterations in the expression of multidrug resistance (MDR)-related genes and proteins. Nude mice were injected with Hep3B/5-Fu cells to establish subcutaneous… More >

  • Open Access

    ARTICLE

    PHLDA2 reshapes the immune microenvironment and induces drug resistance in hepatocellular carcinoma

    KUN FENG1,#, HAO PENG2,#, QINGPENG LV1, YEWEI ZHANG1,*

    Oncology Research, Vol.32, No.6, pp. 1063-1078, 2024, DOI:10.32604/or.2024.047078 - 23 May 2024

    Abstract Hepatocellular carcinoma (HCC) is a malignancy known for its unfavorable prognosis. The dysregulation of the tumor microenvironment (TME) can affect the sensitivity to immunotherapy or chemotherapy, leading to treatment failure. The elucidation of PHLDA2’s involvement in HCC is imperative, and the clinical value of PHLDA2 is also underestimated. Here, bioinformatics analysis was performed in multiple cohorts to explore the phenotype and mechanism through which PHLDA2 may affect the progression of HCC. Then, the expression and function of PHLDA2 were examined via the qRT-PCR, Western Blot, and MTT assays. Our findings indicate a substantial upregulation of… More >

  • Open Access

    REVIEW

    Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review

    EFFAT ALEMZADEH1, LEILA ALLAHQOLI2, AFROOZ MAZIDIMORADI3, ESMAT ALEMZADEH1,4, FAHIMEH GHASEMI4,5, HAMID SALEHINIYA6, IBRAHIM ALKATOUT7,*

    Oncology Research, Vol.32, No.5, pp. 831-847, 2024, DOI:10.32604/or.2024.031006 - 23 April 2024

    Abstract Ovarian cancer is among the most lethal gynecological cancers, primarily due to the lack of specific symptoms leading to an advanced-stage diagnosis and resistance to chemotherapy. Drug resistance (DR) poses the most significant challenge in treating patients with existing drugs. The Food and Drug Administration (FDA) has recently approved three new therapeutic drugs, including two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and niraparib) and one vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) for maintenance therapy. However, resistance to these new drugs has emerged. Therefore, understanding the mechanisms of DR and exploring new approaches to overcome More >

  • Open Access

    ARTICLE

    Extensive prediction of drug response in mutation-subtype-specific LUAD with machine learning approach

    KEGANG JIA1,#, YAWEI WANG2,#, QI CAO3,*, YOUYU WANG1,*

    Oncology Research, Vol.32, No.2, pp. 409-419, 2024, DOI:10.32604/or.2023.042863 - 28 December 2023

    Abstract Background: Lung cancer is the most prevalent cancer diagnosis and the leading cause of cancer death worldwide. Therapeutic failure in lung cancer (LUAD) is heavily influenced by drug resistance. This challenge stems from the diverse cell populations within the tumor, each having unique genetic, epigenetic, and phenotypic profiles. Such variations lead to varied therapeutic responses, thereby contributing to tumor relapse and disease progression. Methods: The Genomics of Drug Sensitivity in Cancer (GDSC) database was used in this investigation to obtain the mRNA expression dataset, genomic mutation profile, and drug sensitivity information of NSCLS. Machine Learning… More >

  • Open Access

    ARTICLE

    Identification of TNFRSF1A as a novel regulator of carfilzomib resistance in multiple myeloma

    JIE ZHAO1,#, XUANTAO YANG2,#, HAIXI ZHANG1, XUEZHONG GU1,*

    Oncology Research, Vol.32, No.2, pp. 325-337, 2024, DOI:10.32604/or.2023.030770 - 28 December 2023

    Abstract Multiple myeloma (MM) is a hematological tumor with high mortality and recurrence rate. Carfilzomib is a new-generation proteasome inhibitor that is used as the first-line therapy for MM. However, the development of drug resistance is a pervasive obstacle to treating MM. Therefore, elucidating the drug resistance mechanisms is conducive to the formulation of novel therapeutic therapies. To elucidate the mechanisms of carfilzomib resistance, we retrieved the GSE78069 microarray dataset containing carfilzomib-resistant LP-1 MM cells and parental MM cells. Differential gene expression analyses revealed major alterations in the major histocompatibility complex (MHC) and cell adhesion molecules.… More >

  • Open Access

    ARTICLE

    Cisplatin-induced activation of TGF-β signaling contributes to drug resistance

    SAYAKA IMATSUJI1,#, YUKIKO UJIE1,#, HIROYUKI ODAKE1, MASAYA IMOTO1,2, SUSUMU ITOH3, ETSU TASHIRO1,3,*

    Oncology Research, Vol.32, No.1, pp. 139-150, 2024, DOI:10.32604/or.2023.030190 - 15 November 2023

    Abstract Growing evidence suggests an association between epithelial-mesenchymal transition (EMT), a hallmark of tumor malignancy, and chemoresistance to a number of anti-cancer drugs. However, the mechanism of EMT induction in the process of acquiring anti-cancer drug resistance remains unclear. To address this issue, we obtained a number of cisplatin-resistant clones from LoVo cells and found that almost all of them lost cell-cell contacts. In these clones, the epithelial marker E-cadherin was downregulated, whereas the mesenchymal marker N-cadherin was upregulated. Moreover, the expression of EMT-related transcription factors, including Slug, was elevated. On the other hand, the upregulation More >

  • Open Access

    ARTICLE

    Inhibition of apoptosis-regulatory protein Siva-1 reverses multidrug resistance in gastric cancer by targeting PCBP1

    FANBIAO KONG1,2,#, KUN WU3,4,#, LIMING PANG2,#, YULIANG HUANG2,#, LEI LI3, JING XU2, FEITONG LI2, YAN QING2, ZHONGYU WANG2, XIURONG HUANG3, SHENG XU2, XIAOGANG ZHONG2, ZHOU ZHU2, XIAOTONG WANG3,*, JIANRONG YANG5,*

    Oncology Research, Vol.30, No.6, pp. 277-288, 2022, DOI:10.32604/or.2022.027301 - 09 February 2023

    Abstract Introduction: Siva-1, as a pro-apoptotic protein, has been shown to induce extensive apoptosis in a number of different cell lines. In our previous study, we showed that overexpressed Siva-1 decreased the apoptosis of gastric cancer cells. So, we believe that it can also work as an anti-apoptotic protein. The present study aimed to determine the specific role of Siva-1 in anticancer drug resistance in gastric cancer in vivo and in vitro and preliminarily reveal the mechanism. Materials and Methods: A vincristine-resistant MKN-28/VCR gastric cancer cell line with stably downregulated Siva-1 was established. The effect of Siva-1 downregulation… More >

  • Open Access

    ARTICLE

    Konjac glucomannan enhances 5-FU-induced cytotoxicity of hepatocellular carcinoma cells via TLR4/PERK/CHOP signaling to induce endoplasmic reticulum stress

    YONGKANG SHI, JUN MA, KE CHEN, BIN CHEN*

    Oncology Research, Vol.30, No.4, pp. 201-210, 2022, DOI:10.32604/or.2022.027584 - 31 January 2023

    Abstract 5-Fluorouracil (5-FU) is a commonly used chemotherapeutic agent for various cancers. However, the drug resistance developed by tumor cells hinders the therapeutic effect. Konjac glucomannan (KGM) is indicated to sensitize 5-FU-resistant hepatocellular carcinoma (HCC) cells to 5-FU. In our study, we found that KGM or 5-FU treatment alone did not affect the malignant cell behaviors and endoplasmic reticulum (ER) stress of 5-FU-resistant HCC cells or HepG2/5-FU and Bel-7402/5-FU cells, while cotreatment with KGM and 5-FU significantly facilitated HCC cell apoptosis and ER stress and suppressed cell proliferation potential and migration abilities. Moreover, we explored the… More >

  • Open Access

    REVIEW

    circRNAs in drug resistance of breast cancer

    SEMA MISIR1,*, SERAP OZER YAMAN2, NINA PETROVIĆ3,4, CEREN SUMER5, CEYLAN HEPOKUR1, YUKSEL ALIYAZICIOGLU2

    Oncology Research, Vol.30, No.4, pp. 157-172, 2022, DOI:10.32604/or.2022.027547 - 31 January 2023

    Abstract Breast cancer (BC) is the most common heterogeneous disease in women and one of the leading causes of cancer-related death. Surgery, chemotherapy, radiotherapy, hormone, and targeted therapy are the gold standards for BC treatment. One of the significant challenges during the treatment of BC represents resistance to chemotherapeutics, resistance that severely limits the use and effectiveness of the drugs used for BC treatment. Therefore, it is essential to develop new strategies to improve therapeutic efficacy. Circular RNAs (circRNAs) are a large group of non-coding RNAs that covalently form closed circular loops by joining their 5′,… More >

  • Open Access

    ARTICLE

    The synergistic effects of PRDX5 and Nrf2 on lung cancer progression and drug resistance under oxidative stress in the zebrafish models

    SITONG QIAN1,2,#, YING FANG1,#, CHENGYUN YAO1,#, YONGSHENG WANG3,#, ZHI ZHANG1, XIAOHUA WANG1, JIN GAO1, YONG FENG1, LEI SUN1, RUNYUE ZOU2, GUOREN ZHOU1,*, JINJUN YE1,*, RUIXUE XIA4,*, HONGPING XIA5,6,*

    Oncology Research, Vol.30, No.2, pp. 53-64, 2022, DOI:10.32604/or.2022.026302 - 05 January 2023

    Abstract Previous studies have shown that PRDX5 and Nrf2 are antioxidant proteins related to abnormal reactive oxidative species (ROS). PRDX5 and Nrf2 play a critical role in the progression of inflammations and tumors. The combination of PRDX5 and Nrf2 was examined by Co-immunoprecipitation, western blotting and Immunohistochemistry. H2O2 was applied to affect the production of ROS and induced multi-resistant protein 1 (MRP1) expression in NSCLC cells. The zebrafish models mainly investigated the synergistic effects of PRDX5 and Nrf2 on lung cancer drug resistance under oxidative stress. We showed that PRDX5 and Nrf2 form a complex and significantly More >

Displaying 1-10 on page 1 of 34. Per Page